This is an investigational study. Inotuzumab ozogamicin is not FDA-approved or commercially available. Bosutinib is FDA-approved and commercially available for the treatment of certain types of CML in patients who have failed previous therapies. It is considered investigational to use this combination of drugs to treat Ph+ AML/CML.